First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. - Wikidata - wikimedia - TriplyDB

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.

http://www.wikidata.org/entity/Q39083050

about

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease New Features about Tau Function and Dysfunction Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers Tau Biology and Tau-Directed Therapies for Alzheimer's Disease Can oral infection be a risk factor for Alzheimer's disease?Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations.Strategies for dementia prevention: latest evidence and implications.Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Tau Immunotherapy.Developing therapeutic vaccines against Alzheimer's disease.Tau and neurodegenerative disease: the story so far.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells.Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach Metabolic status of CSF distinguishes rats with tauopathy from controls.Emerging Diagnostic and Therapeutic Strategies for Tauopathies.The past, present, and future of disease-modifying therapies for Alzheimer's disease.Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.Tau Proteins and Tauopathies in Alzheimer's Disease.Tauopathies: Mechanisms and Therapeutic Strategies."Tau immunotherapy: Hopes and hindrances".Vaccination strategies in tauopathies and synucleinopathies.Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead

P2860

Q26739412-FB45433B-533C-46C8-ABD5-BEA3CD889753 Q26750922-CC6B6421-1FB9-4792-ABF5-1DAF556B9E2F Q26765530-A181D85F-F112-4313-9F22-6AFA91D868CB Q27305025-7D010CC1-BFE6-44EB-BAE7-D229D0A0F9B0 Q28071398-E2F0B664-8726-4869-89C9-FB0CDEB6C16E Q33361553-58798C4F-2B8A-4A9C-B40F-9499CD4689C9 Q33640390-DB0CBCE0-8549-4FB3-BD38-D120996B0C80 Q33887379-A8399E4C-2CD2-4D86-B8B5-45E8E2EE0C8D Q34518856-F17C2695-055C-4E2D-A703-0A36EF22E643 Q36240389-41CE0C80-5CBA-43D3-8E33-880411BAD8A0 Q36484413-9CB83756-D035-462C-865C-B9AB743F257F Q36970998-1FC9160D-F8CF-4DFB-A71E-A68ED531A3AD Q37610545-23B42F67-CC49-4730-ACD1-1ED459A86571 Q38540633-198D8B18-941E-4C3A-BFAF-1870FD5FA8BF Q38621253-09758A26-FB6A-4285-AB44-7DA04539D5D2 Q38625515-52F63C5B-0745-4E6C-866C-C1F4061D8A82 Q38628672-DA55C458-A3F2-4961-A87C-659C3CF454CD Q38636151-F37B39D6-21F7-4045-9CA7-37511F62317E Q38658752-E4CCC307-9633-46B8-9B64-34F92FEDA910 Q38715233-74117943-5FC5-41CF-A41D-E599B72639E8 Q38892738-F28A3A10-C27F-4363-83BF-198790317E86 Q38970893-4BDFE978-C3A6-4FFE-8B05-821BA2FD803D Q40990185-EE774E77-913A-4737-B439-23258538848C Q41629521-34A5CF7C-35C6-4033-BC0D-9476B514C98F Q41690749-9FD66DDF-8D0C-44D9-BBDA-18DE96CF0351 Q45870549-413FAD14-6955-42DA-BAAD-DC99B9874998 Q46244313-8AEB9BFE-75B0-4754-9AB2-9FCDEF1BA3B0 Q47222390-A9405F65-4363-4670-8262-577DAB96B985 Q47233523-EDBA1EE0-A6E4-4DAE-8656-DB817F4A1CE9 Q47253592-97BEF8E4-B51F-452C-90DC-F8C9CF5DF2DC Q47629452-98FBA992-877B-4D50-85A1-D0598F9FEFE9 Q47860105-B327ECB2-C4D7-430F-BA13-840991A6C55D Q50045202-51552D3B-12D3-4074-8B19-3CB7CC4E8E68 Q50532471-8CCCEE17-4265-4097-A528-F6298600FF00 Q50632272-E5D4FE10-3F82-4FE5-8543-E659538B4100 Q55345450-112CFBF8-2F7A-4BA5-ACA1-D8950903E926 Q57927766-F16DC83E-12FA-4C58-AA2F-7C79CF3F93D2 Q59137449-C89C82D8-F1EF-4922-9613-C9CCEB3AC781

P2860

First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.

http://www.wikidata.org/entity/Q39083050

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@en

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@nl

type

label

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@en

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@nl

prefLabel

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@en

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@nl

P1433

Q39083050-7BF3DA52-E245-472B-85EE-024337325797

P1476

Q39083050-A1E50DE9-3360-4629-9DF3-C83E5929CFA5

P2093

Q39083050-097FCD60-921E-46DD-9FB3-AE598BD35C21

Q39083050-18263722-EFAE-4B02-ABB8-2209A1DCFF06

Q39083050-604720E0-32D6-4A0F-882D-6384E7E16A29

Q39083050-70173F2D-52A1-48C3-A34B-A307D976A11D

Q39083050-BD7A137E-97EB-4944-98A2-C529ECBD37DF

P2860

Q39083050-00011F86-02E0-4297-B6FB-CEA0C746A40A

Q39083050-00744723-666B-4F09-85F0-4F5BF1EA5EEA

Q39083050-04092A04-7A18-48F8-AFC2-3B5A0D853F9E

Q39083050-097180FA-EFAF-4800-8640-109FC4462852

Q39083050-0CB9974A-1184-44AD-A8F5-81B6E0454FB4

Q39083050-152FF507-D6A3-40F2-A2EB-5D85E354FD00

Q39083050-197C59C9-E592-4DCB-ADA4-B2BA27D5C888

Q39083050-1A71175B-E7A4-4972-B417-5B923C60EBF6

Q39083050-1ABECD8C-90EB-47BC-B029-BF275A4E8F7F

Q39083050-2D5ECBFA-292D-4C10-906A-9AAE5C932A02

P2888

Q39083050-D60626B6-7E73-4E23-9727-C0DE6AAE1F2D

P304

Q39083050-54C6EFFF-D9C7-4579-9DA7-D267E0C5BCE0

P31

Q39083050-269ED872-A1EB-40E0-A742-1D8328686AF5

P356

Q39083050-2FD92679-F1AF-415B-9A13-C0189505B13F

P407

Q39083050-5ADA00CD-AD54-4F97-8367-724F86F2476E

P433

Q39083050-BAD05D23-91B7-42C9-AB85-6FABC1047B98

P478

Q39083050-62222D65-6631-4794-9E04-58E60EDCA0D7

P577

Q39083050-38B8D142-7950-41A5-8B21-E2BD5BCC5DC0

P5875

Q39083050-694B1693-0788-4AF3-8E2C-67AF9C6B5993

P6179

Q39083050-6B0CC445-C667-4F24-952F-BF664A3DE1DC

P698

Q39083050-4B946EAA-129E-4F36-872C-381C9447636D

P921

Q39083050-E0BCF01D-5AF9-4264-BED6-758D620A9435

P932

Q39083050-E182782C-D122-4FD9-95B2-ABD8F767C138

P356

P1433

Alzheimers Research & Therapy

P1476

First-in-man tau vaccine targe ...... an Alzheimer's disease model.

@en

P2093

Branislav Kovacech

http://www.w3.org/2001/XMLSchema#string

Eva Kontsekova

http://www.w3.org/2001/XMLSchema#string

Michal Novak

http://www.w3.org/2001/XMLSchema#string

Norbert Zilka

http://www.w3.org/2001/XMLSchema#string

Petr Novak

http://www.w3.org/2001/XMLSchema#string

P2860

Immunotherapy as treatment for Alzheimer’s disease

Immunotherapy for Alzheimer's disease: hoops and hurdles

Tau-targeted treatment strategies in Alzheimer's disease

Neuropathological stageing of Alzheimer-related changes

Alzheimer's disease: clinical trials and drug development.

Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice.

Motor signs predict poor outcomes in Alzheimer disease.

Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

P2888

P304

44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/ALZRT278

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269172259

http://www.w3.org/2001/XMLSchema#string

P6179

1042088002

http://www.w3.org/2001/XMLSchema#string

P698

25478017

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4255368

http://www.w3.org/2001/XMLSchema#string